Anon. n.d.-a. ‘Antipsychotics Increase Mortality in Elderly Patients with Dementia’. Retrieved (http://www.npc.nhs.uk/merec/cns/dementia/merec_extra_no39.php).
Anon. n.d.-b. ‘Aricept Tablets - Summary of Product Characteristics (SPC) - (eMC)’. Retrieved (http://www.medicines.org.uk/emc/medicine/577/SPC/Aricept).
Anon. n.d.-c. ‘British National Formulary’. Retrieved (http://www.bnf.org/bnf/index.htm).
Anon. n.d.-d. ‘Centre for Medicines Optimisation - MTRAC | Independent Medicines Review | Midlands Therapeutics Review & Advisory Committee | Centre for Medicines Optimisation | Keele University’. Retrieved (http://centreformedicinesoptimisation.co.uk/mtrac/).
Anon. n.d.-e. ‘Chronic Obstructive Pulmonary Disease’. Retrieved (http://cks.nice.org.uk/chronic-obstructive-pulmonary-disease).
Anon. n.d.-f. ‘Clinical Guidelines, CG42 - Issued: November 2006’. Retrieved (http://guidance.nice.org.uk/CG42).
Anon. n.d.-g. ‘Coeliac Disease: Recognition, Assessment and Management  | Guidance and Guidelines | NICE’.
Anon. n.d.-h. ‘Commissioners and Healthcare Professionals - Training Videos’. Retrieved (http://healthcheck.nhs.uk/commissioners_and_providers/training/training_videos1/).
Anon. n.d.-i. ‘Complete Guide to Behavioural and Psychological Symptoms of Dementia’. Retrieved (http://www.ipa-online.org/).
Anon. n.d.-j. ‘CPPE - Centre for Pharmacy Postgraduate Education’. Retrieved (https://www.cppe.ac.uk/).
Anon. n.d.-k. ‘DH Living Well with Dementia: A National Dementia Strategy’. Retrieved (https://www.gov.uk/government/organisations/department-of-health).
Anon. n.d.-l. ‘Ebixa 5mg/Pump Actuation Oral Solution, 20mg and 10 Mg Tablets and Treatment Initiation Pack - Summary of Product Characteristics (SPC) - (eMC)’. Retrieved (http://www.medicines.org.uk/EMC/medicine/10175/SPC/rEbxia+5mg+pump+oral+solution%252c+20mg+and+10+mg+tablets+and+Treatment+Initiation+Pack/).
Anon. n.d.-m. ‘Electronic Medicines Compendium (eMC)’. Retrieved (http://www.medicines.org.uk/emc/).
Anon. n.d.-n. ‘Electronic Medicines Compendium (eMC)’. Retrieved (http://www.medicines.org.uk/emc/).
Anon. n.d.-o. ‘Electronic Medicines Compendium (eMC)’. Retrieved (https://www.medicines.org.uk/emc/).
Anon. n.d.-p. ‘Evidence Search - Search Engine for Evidence in Health and Social Care’. Retrieved (https://www.evidence.nhs.uk/).
Anon. n.d.-q. ‘Evidence Search - Search Engine for Evidence in Health and Social Care’. Retrieved (https://www.evidence.nhs.uk/).
Anon. n.d.-r. ‘Evidence Search - Search Engine for Evidence in Health and Social Care’. Retrieved (https://www.evidence.nhs.uk/).
Anon. n.d.-s. ‘Exelon - Summary of Product Characteristics (SPC) - (eMC)’. Retrieved (https://www.medicines.org.uk/emc/search?q=Exelon+).
Anon. n.d.-t. ‘GOV.UK’. Retrieved (https://www.gov.uk/government/organisations/department-of-health).
Anon. n.d.-u. ‘Heart Failure - Chronic’. Retrieved (http://cks.nice.org.uk/heart-failure-chronic).
Anon. n.d.-v. ‘Map of Medicine | Home’. Retrieved (http://www.mapofmedicine.com/).
Anon. n.d.-w. ‘Medicines Information - Evidence Search - Search Engine for Evidence in Health and Social Care’. Retrieved (https://www.evidence.nhs.uk/).
Anon. n.d.-x. ‘Medicines Use Review and Prescription Intervention Service’.
Anon. n.d.-y. ‘National Institute for Health and Care Excellence’. Retrieved (http://www.nice.org.uk/).
Anon. n.d.-z. ‘NHS Health Check - NHS Choices’. Retrieved (http://www.nhs.uk/Conditions/nhs-health-check/Pages/NHS-Health-Check.aspx).
Anon. n.d.-aa. ‘NICE Clinical Knowledge Summaries (CKS)’. Retrieved (http://cks.nice.org.uk/).
Anon. n.d.-ab. ‘NPC | National Prescribing Centre’. Retrieved (https://www.guidelinesinpractice.co.uk).
Anon. n.d.-ac. ‘NPC | National Prescribing Centre’. Retrieved (https://www.guidelinesinpractice.co.uk).
Anon. n.d.-ad. ‘Optimising Treatment and Care for Behavioural and Psychological Symptoms of Dementia: A Best Practice Guide’. Retrieved (https://www.alzheimers.org.uk/bpsdguide).
Anon. n.d.-ae. ‘Reminyl Tablets - Summary of Product Characteristics (SPC) - (eMC)’.
Anon. n.d.-af. ‘Risperdal Tablets, Liquid & Quicklet - Summary of Product Characteristics (SPC) - (eMC)’. Retrieved (http://www.medicines.org.uk/emc/document.aspx?documentid=12818&docType=SPC).
Anon. n.d.-ag. ‘Royal Pharmaceutical Society (RPS)’. Retrieved (http://www.rpharms.com/home/home.asp).
Anon. n.d.-ah. ‘Scottish Intercollegiate Guidelines Network (SIGN)’. Retrieved (http://www.sign.ac.uk/).
Anon. n.d.-ai. ‘Service Specification - New Medicine Service (NMS)’.
Anon. n.d.-aj. ‘TA217 Alzheimer’s Disease - Donepezil, Galantamine, Rivastigmine and Memantine: Guidance (MS Word Format)’. Retrieved (http://guidance.nice.org.uk/TA217/Guidance/doc/English).
Anon. n.d.-ak. ‘Treatment Protocol by NHS Medway: Treatment of  Behaviour That Challenges’. Retrieved (http://www.kmpt.nhs.uk/policies).
Bhasin, Mani, Elise Rowan, Keith Edwards, and Ian McKeith. 2007. ‘Cholinesterase Inhibitors in Dementia with Lewy Bodies—a Comparative Analysis’. International Journal of Geriatric Psychiatry 22(9):890–95. doi: 10.1002/gps.1759.
Greene, Russell J., and Norman D. Harris. 2008. Pathology and Therapeutics for Pharmacists: A Basis for Clinical Pharmacy Practice. 3rd ed. London: Pharmaceutical Press.
Hubley, John, June Copeman, and James Woodall. 2013. Practical Health Promotion. 2nd ed. Cambridge: Polity Press.
Kavirajan, Harish, and Lon S. Schneider. 2007. ‘Efficacy and Adverse Effects of Cholinesterase Inhibitors and Memantine in Vascular Dementia: A Meta-Analysis of Randomised Controlled Trials’. The Lancet Neurology 6(9):782–92. doi: 10.1016/S1474-4422(07)70195-3.
Kumar, Parveen J., and Michael L. Clark. 2012. Kumar & Clark’s Clinical Medicine. 8th ed. Edinburgh: Saunders Elsevier.
Laverack, Glenn. 2007. Health Promotion Practice: Building Empowered Communities. Maidenhead: Open University Press.
Macdowall, Wendy, Chris Bonell, and Maggie Davies. 2006. Health Promotion Practice. Vol. Understanding public health. Maidenhead: Open University Press.
Maher, Alicia Ruelaz. 2011. ‘Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in AdultsA Systematic Review and Meta-Analysis’. JAMA: The Journal of the American Medical Association 306(12). doi: 10.1001/jama.2011.1360.
Maher, Alicia Ruelaz, Margaret Maglione, Steven Bagley, Marika Suttorp, Jian-Hui Hu, Brett Ewing, Zhen Wang, Martha Timmer, David Sultzer, and Paul G. Shekelle. 2011. ‘Efficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults’. JAMA 306(12). doi: 10.1001/jama.2011.1360.
Martinón-Torres, Georgina, Mario Fioravanti, and John Grimley Evans. 2004. ‘Trazodone for Agitation in Dementia’. Cochrane Database of Systematic Reviews. doi: 10.1002/14651858.CD004990.
Miller, William R., and Stephen Rollnick. 2013. Motivational Interviewing: Helping People Change. Vol. Applications of motivational interviewing. 3rd ed. New York: Guilford Press.
Pierre N. Tariot, M.D.; Rosemary Erb, R.N., B.S.N.; Carol Ann Podgorski, Ph.D.; Christopher Cox, Ph.D.; Shirish Patel, M.D.; Laura Jakimovich, M.S., R.N.; Carrie Irvine, B.A. 1998. ‘Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia’. PsychiatryOnline | American Journal of Psychiatry | Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia 155(1):54–61. doi: 10.1176/ajp.155.1.54.
Prochaska, James O., John C. Norcross, and Carlo C. DiClemente. 1994. Changing for Good. New York: William Morrow.
Rollnick, Stephen, Pip Mason, and Christopher Butler. 1999. Health Behavior Change: A Guide for Practitioners. Edinburgh: Churchill Livingstone.
Rollnick, Stephen, William R. Miller, and Christopher Butler. 2008. Motivational Interviewing in Health Care: Helping Patients Change Behavior. Vol. Applications of motivational interviewing. New York: Guilford Press.
Sube Banerjee. 12AD. ‘The Use of Antipsychotic Medication for People with Dementia: Time for Action. A Report for the Minister of State for Care Services’.
Waldemar, Gunhild, Maritta Hyvärinen, Mette Krog Josiassen, Alex Kørner, Heikki Lehto, and Peter Wetterberg. 2008. ‘Tolerability of Switching from Donepezil to Memantine Treatment in Patients with Moderate to Severe Alzheimer’s Disease’. International Journal of Geriatric Psychiatry 23(9):979–81. doi: 10.1002/gps.1979.
Walker, Roger, and Cate Whittlesea. 2012. Clinical Pharmacy and Therapeutics. 5th ed. Edinburgh: Churchill Livingstone.
Warner, James, and Tom Smith. n.d. ‘The Rise and Fall of Antipsychotic Prescribing in Dementia. Where Do We Go from Here?’ The Rise and Fall of Antipsychotic Prescribing in Dementia 14(2):24–27.